Cours suspendu

Autres langues Intra-Cellular Therapies, Inc.

Actions

ITCI

US46116X1019

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 01/04/2025			Varia. 5j.	Varia. 1 janv.
131,87 ^USD	-0,04%		-.--%	-

02/04/25	Johnson & Johnson finalise l'achat de Intra-Cellular Therapies	MT
02/04/25	J&J : acquisition imminente de Intra-Cellular Therapies

Autres langues

15/04/25	J&J Boosts Outlook Despite Incoming Tariff Costs -- Update
15/04/25	MIDDAY BRIEFING - Unternehmen und Märkte -2-
15/04/25	J&J Increases Outlook After Beating 1Q Expectations
15/04/25	Intra-Cellular Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
03/04/25	Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from S&P Pharmaceuticals Select Industry Index
03/04/25	Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from S&P TMI Index
03/04/25	Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from S&P Global BMI Index
02/04/25	Johnson & Johnson Completes Intra-Cellular Therapies Purchase
02/04/25	J&J: about to acquire Intra-Cellular Therapies
02/04/25	Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition
02/04/25	Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from NASDAQ Composite Index
02/04/25	Johnson & Johnson Innovative Medicine completed the acquisition of Intra-Cellular Therapies, Inc. from a group of shareholders.
01/04/25	Johnson & Johnson Expects Lower EPS Impact From Intra-Cellular Deal
01/04/25	Johnson & Johnson Announces Expected Closing Date For Intra-Cellular Acquisition
01/04/25	Intra Cellular Therapies : Leonteq Securities AG Übernahme/Fusion/Spin off (Sponsored Segment)
01/04/25	Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from NASDAQ Biotechnology Index
26/03/25	Jefferies profit misses estimates as bond trading, equity underwriting weaken
18/03/25	Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court
07/03/25	J&J: end of a trial on a treatment for depression
06/03/25	J&J to stop studies of depression drug due to low effectiveness
25/02/25	INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
25/02/25	Analyst recommendations: Block, Lucid, Celsius, Dun & Bradstreet, Sentinelone...
24/02/25	Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
21/02/25	Intra-Cellular: Q4 Earnings Snapshot
21/02/25	Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises